Nomura Holdings Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Nomura Holdings Inc

$50.5 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $6.49 Million - $10.7 Million	-257,817 Reduced 33.87%	503,330 $17.9 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $2.64 Million - $4.3 Million	111,599 Added 17.18%	761,147 $19.3 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $17.7 Million - $25.7 Million	633,827 Added 4031.72%	649,548 $26.3 Million
Q3 2022 Nov 15, 2022	SELL	$29.63 - $48.31 $5.84 Million - $9.53 Million	-197,200 Reduced 92.62%	15,721 $520,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $5.52 Million - $10.1 Million	198,799 Added 1407.73%	212,921 $7.66 Million
Q1 2022 May 18, 2022	SELL	$39.62 - $69.97 $5.55 Million - $9.81 Million	-140,176 Reduced 90.85%	14,122 $695,000
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $852,180 - $1.21 Million	14,670 Added 10.51%	154,298 $10.2 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $2.13 Million - $3.09 Million	-36,422 Reduced 20.69%	139,628 $8.73 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $7.74 Million - $11.2 Million	124,462 Added 241.26%	176,050 $14.6 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $12.1 Million - $17.8 Million	-197,069 Reduced 79.25%	51,588 $3.43 Million
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $10.5 Million - $20.5 Million	239,707 Added 2678.29%	248,657 $19.1 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $141,142 - $217,897	-4,250 Reduced 32.2%	8,950 $385,000
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $1.14 Million - $1.9 Million	-43,800 Reduced 76.84%	13,200 $568,000
Q1 2020 May 14, 2020	BUY	$20.56 - $63.12 $1.17 Million - $3.6 Million	57,000 New	57,000 $1.64 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.

Account